This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to
investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical
efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in
participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC,
ovarian cancer, CRPC, TNBC, bladder cancer, and specified GI malignancies (defined as CRC,
gastric/GEJ cancer, HCC, PDAC, or SCAC)
Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.